Drug intelligence / Profile preview

MRG-002

Development stage: Preclinical
Lead developer: MedRegen
Modality: Small Molecules
Administration: Intravenous

Overview

**MRG-002** is a preclinical fixed-dose combination developed by MedRegen for skin-related wound injuries and certain liver diseases. It combines plerixafor, a C-X-C chemokine receptor type 4 antagonist, with FKVP, a novel non-immunosuppressive tacrolimus analog reported to activate bone morphogenetic protein signaling without inhibiting calcineurin. ([medregenco.com](https://www.medregenco.com/mrg-002/))

Other names: plerixafor + FKVP

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on MRG-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRG-002.

Explore the full profile